Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys

Neuropsychopharmacology

Volumn 33, Issue 2, 2008, Pages 219-225

  Banks, Matthew L ^a   Czoty, Paul W ^a   Gage, H Donald ^a   Bounds, Michael C ^a   Garg, Pradeep K ^a   Garg, Sudha ^a   Nader, Michael A ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Cocaine; MDMA; Nonhuman primates; PET; Self administration; Serotonin transporters

Indexed keywords

3 AMINO 4 (2 DIMETHYLAMINOMETHYLPHENYLSULFANYL)BENZONITRILE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CARBON 11; COCAINE; RADIOLIGAND; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUDATE NUCLEUS; CEREBELLUM; CINGULATE GYRUS; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RAT; RHESUS MONKEY;

ANIMALS; CAUDATE NUCLEUS; COCAINE; GYRUS CINGULI; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; SELF ADMINISTRATION; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 36849086375     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301420     Document Type: Article

References (60)

1. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988). Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149: 159-163.
2. Beardsley PM, Balster RL, Harris LS (1986). Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend 18: 149-157.
3. Bennett BA, Wichems CH, Hollingsworth CK, Davies HM, Thornley C, Sexton T et al (1995). Novel 2-substituted cocaine analogs: uptake and ligand binding studies at dopamine, serotonin and norepinephrine transport sites in the rat brain. J Pharmacol Exp Ther 272: 1176-1186.
4. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L et al (2003). Long-term effects of 'ecstasy' use on serotonin transporters of the brain investigated by PET. J Nucl Med 44: 375-384.
5. Buchert R, Thomasius R, Petersen K, Wilke F, Obrocki J, Nebeling B et al (2006). Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. Eur J Nucl Med Mol Imaging 33: 188-199.
6. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J et al (2004). A voxel-based PET investigation of the long-term effects of 'ecstasy' consumption on brain serotonin transporters. Am J Psychiatry 161: 1181-1189.
7. Burmeister JJ, Lungren EM, Neisewander JL (2003). Effects of fluoxetine and d-fenfluramine on cocaine-seeking behavior in rats. Psychopharmacology 168: 146-154.
8. Buydens-Branchey L, Branchey M, Hudson J, Rothman M, Fergeson P, McKernin C (1998). Effect of fenfluramine challenge on cocaine craving in addicted male users. Am J Addict 7: 142-155.
9. Cunningham KA, Paris JM, Goeders NE (1992). Chronic cocaine enhances serotonin autoregulation and serotonin uptake binding. Synapse 11: 112-123.
10. Czoty PW, Ginsburg BC, Howell LL (2002). Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 300: 831-837.
11. Czoty PW, Martelle JL, Nader MA (2006). Influence of abstinence and conditions of cocaine access on the reinforcing strength of cocaine in nonhuman primates. Drug Alcohol Depend 85: 213-220.
12. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE (1994). Performance characteristics of a whole-body PET scanner. J Nucl Med 35: 1398-1406.
13. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278.
14. Dworkin SI, Mirkis S, Smith JE (1995). Response-dependent versus response-independent presentation of cocaine: differences in the lethal effects of the drug. Psychopharmacology 117: 262-266.
15. Fantegrossi WE (2007). Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity? Psychopharmacology 189: 471-482.
16. Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidmitriou G et al (2004). Behavioral and neurochemical consequences of long-term self-administration of MDMA and its enantiomers in rhesus monkeys. Neuropsychopharmacology 29: 1270-1281.
17. 11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Syanpse 47: 123-133.
18. Glatz AC, Ehrlich M, Bae RS, Clarke MJ, Quinlan PA, Brown EC et al (2002). Inhibition of cocaine self-administration by fluoxetine or d-fenfluramine combined with phentermine. Pharmacol Biochem Behav 71: 197-204.
19. Goldstein RZ, Volkow ND (2002). Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159: 1642-1652.
20. Gouzoulis-Mayfrank E, Daumann J (2006). The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol 20: 188-193.
21. Grabowski J, Rhoades H, Elk R, Schmitz J, Davis C, Creson D et al (1995). Fluoxetine is ineffective for the treatment of cocaine dependence or current opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol 15: 163-174.
22. Hemby SE, Co C, Koves TR, Smith JE, Dworkin SI (1997). Differences in extracellular dopamine concentrations in the nucleus accumbens during response-dependent and response-independent cocaine administration in the rat. Psychopharmacology 133: 7-16.
23. 11C] DASB. Eur J Nucl Med 27: 1719-1722.
24. Howell LL, Carroll FI, Votaw JR, Goodman MM, Kimmel HL (2007). Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther 320: 757-765.
25. Hummerich R, Geischl G, Ehrlichmann W, Machulla HJ, Heinz A, Schloss P (2004). DASB - in vitro binding characteristics on human recombinant monoamine transporters with regard to its potential as positron emission tomography (PET) tracer. J Neurochem 90: 1218-1226.
26. Jacobsen LK, Staley JK, Malison RT, Zoghbi SS, Seibyl JP, Kosten TR et al (2000). Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry 157: 1134-1140.
27. Kleven MS, Woolverton WL (1993). Effects of three monoamine reuptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys. Drug Alcohol Depend 31: 149-158.
28. Koch S, Galloway MP (1997). MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104: 135-146.
29. Letchworth SR, Nader MA, Smith HR, Friedman DP, Porrino LJ (2001). Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys. J Neurosci 21: 2799-2807.
30. Lile JA, Morgan D, Birmingham AM, Wang Z, Woolverton WL, Davies HM et al (2003). The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics. J Pharmacol Exp Ther 307: 356-366.
31. Lile JA, Morgan D, Freedland CS, Sinnott RS, Davies HM, Nader MA (2000). Self-administration of two long-acting monoamine transport blockers in rhesus monkeys. Psychopharmacology 152: 414-421.
32. Lile JA, Ross JT, Nader MA (2005). A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') with cocaine in rhesus monkeys. Drug Alcohol Depend 78: 135-140.
33. 3H]WIN 35428 binding sites in human striatum. Brain Res 628: 17-25.
34. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996). Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16: 834-840.
35. Mash DC, Staley JK, Izenwasser S, Basile M, Ruttenber AJ (2000). Serotonin transporters upregulate with chronic cocaine use. J Chem Neuroanat 20: 271-280.
36. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998). Positron emission tomographic evidence of toxic effect of MDMA ('ecstasy') on brain serotonin neurons in human beings. Lancet 352: 1433-1437.
37. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT et al (2005). Quantitative PET studies of the serotonin transporter in MDMA users and controls using [(11)C]McN5652 and [(11)C]DASB. Neuropsychopharmacology 30: 1741-1750.
38. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N et al (2004). Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 61: 1271-1279.
39. 11C]-DASB to the serotonin transporter in baboons: response to acute serotonin deficiency. Biol Psychiatry 57: 102-106.
40. Praschak-Rieder N, Wilson AA, Hussey D, Carella A, Wei C, Ginovart N et al (2005). Effects of tryptophan depletion on the serotonin transporter in healthy humans. Biol Psychiatry 58: 825-830.
41. Ratzenboeck E, Saria A, Kriechbaum N, Zernig G (2001). Reinforcing effects of MDMA ('ecstasy') in drug-naive and cocaine-trained rats. Pharmacology 62: 138-144.
42. Reneman L, Booij J, Habraken JB, De Bruin K, Hatzidimitriou G, Den Heeten GJ et al (2002). Validity of [123]beta-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse 46: 199-205.
43. Richardson NR, Roberts DCS (1991). Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci 49: 833-840.
44. Richardson NR, Roberts DCS (1996). Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66: 1-11.
45. Rothman RB, Baumann MH (2003). Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479: 23-40.
46. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI et al (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
47. Rudnick G, Clark J (1993). From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144: 249-263.
48. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT et al (1998). In vivo detection of short- and long-term MDMA neurotoxicity - a positron emission tomography study in the living baboon brain. Synapse 29: 183-192.
49. Schmitz JM, Averill P, Stotts AL, Moeller FG, Rhoades HM, Grabowski J (2001). Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend 63: 207-214.
50. Smith S (2002). Fast robust automated brain extraction. Hum Brain Mapp 17: 143-155.
51. 3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36: 2297-2303.
52. 11C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 43: 678-692.
53. 11C-DASB in healthy humans. Synapse 55: 164-175.
54. Tancer M, Johanson CE (2007). The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 189: 565-573.
55. Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L et al (2003). Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 167: 85-96.
56. Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L et al (2006). Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 20: 211-225.
57. Walsh SL, Preston KL, Sullivan JT, Fromme R, Bigelow GE (1994). Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 14: 396-407.
58. Wang X, Bauman MH, Xu H, Morales M, Rothman RB (2005). 3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. J Pharmacol Exp Ther 314: 1002-1012.
59. Wang X, Baumann MH, Xu H, Rothman RB (2004). 3,4- Methylenedioxymethamphetamine administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 53: 240-248.
60. Woods RP, Mazziotta JC, Cherry SR (1993). MRI-PET registration with automated algorithm. J Comput Assist Tomogr 17: 536-546.